InterCure closes first tranche of Botanico deal

Rhea-AI Filing Summary

InterCure Ltd. has completed the first tranche (50%) of its acquisition of Israeli cannabis technology and brand company Botanico Ltd. (ISHI), and is launching a strategic review of opportunities in regulated U.S. medical cannabis markets following recent federal rescheduling of certain state-licensed medical cannabis to Schedule III.

Through the Botanico transaction, InterCure gains exclusive rights to a broad collection of award-winning American cannabis genetics, proprietary strains, premium brands and advanced AI-driven, automated production technologies, including alliances with leading U.S. operators such as The Flowery. As part of the initial closing, the company will issue 2,471,061 ordinary shares, with an additional 2,470,073 ordinary shares to be issued upon satisfaction of conditions under the share purchase agreement.

InterCure also reports its first meaningful revenues from Germany’s rapidly growing medical cannabis market, has appointed a local management and sales team, and plans multiple product launches there in the second half of the year, supporting its goal of building a leading international medical cannabis platform.

Positive

• Strategic acquisition expands capabilities: Completion of the first 50% tranche of the Botanico acquisition gives InterCure exclusive access to award-winning U.S. cannabis genetics, premium brands and advanced AI-driven production technologies, strengthening its international medical cannabis platform.
• International growth momentum in Germany: The company reports its first meaningful revenues from Germany’s rapidly growing medical cannabis market, has appointed a German management and sales team, and plans multiple product launches in the second half of the year.

Negative

• None.

Insights

Cannabis sector and cross-border strategy analyst

InterCure deepens international platform via Botanico deal and German growth.

InterCure is using the Botanico acquisition to secure exclusive U.S. genetics, premium brands and AI-driven production technologies. This expands its product and technology base while remaining focused on regulated medical markets rather than broader recreational exposure.

The deal structure includes an initial share issuance of 2,471,061 ordinary shares and a further 2,470,073 shares contingent on conditions under the share purchase agreement. That introduces equity-based consideration and potential dilution, but the filing does not quantify the company’s overall share base for proportional context.

Strategically, management highlights emerging German revenues and added local leadership, with multiple German product launches planned for the second half of the year. The newly announced review of U.S. medical cannabis opportunities after federal rescheduling may lead to future expansion, but timing and specific moves are not detailed here.

Key Figures

First tranche size: 50% of Botanico transaction Initial share issuance: 2,471,061 ordinary shares Additional contingent shares: 2,470,073 ordinary shares +1 more

4 metrics

First tranche size 50% of Botanico transaction Initial closing of acquisition

Initial share issuance 2,471,061 ordinary shares Consideration for initial Botanico closing

Additional contingent shares 2,470,073 ordinary shares To be issued upon satisfaction of conditions

German product launch timing Second half of the year Planned medical cannabis product launches in Germany

Key Terms

federal rescheduling, strategic review, AI-driven technologies, Good Manufacturing Practices (GMP), +1 more

5 terms

federal rescheduling regulatory

"Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III"

strategic review financial

"InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets"

A strategic review is a thorough examination of a company's goals, operations, and plans to determine the best way to move forward. It helps identify strengths, weaknesses, and opportunities, guiding decisions on future actions. For investors, it provides insight into how a company plans to improve performance or adapt to changes, which can influence its long-term prospects.

AI-driven technologies technical

"access to ISHI’s advanced AI-driven technologies, automated production systems"

Computer systems that learn from data to make decisions, spot patterns, or automate tasks without being explicitly programmed for every step. Think of them as self-improving assistants that can speed up work, reduce costs, or create new products and services; for investors, that potential can drive faster revenue growth, higher profit margins, or market disruption but also brings implementation costs, competitive shifts, and regulatory or ethical risks to consider.

Good Manufacturing Practices (GMP) regulatory

"one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products"

Good manufacturing practices (GMP) are the set of rules and controls that ensure drugs, medical devices, and related products are made cleanly, consistently, and to the quality claimed on the label. For investors, GMP matters because meeting these standards reduces the chance of product recalls, production shutdowns, fines, or lost approvals—similar to a restaurant that follows strict recipes and hygiene to avoid food poisoning and keep customers coming back.

forward-looking statements regulatory

"This press release contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did InterCure (INCR) announce regarding the Botanico acquisition?

InterCure announced completion of the first tranche, representing 50% of its acquisition of Botanico Ltd. The deal provides exclusive access to award-winning U.S. cannabis genetics, premium brands and AI-driven technologies that support InterCure’s international medical cannabis strategy.

How many InterCure (INCR) shares are being issued for the Botanico transaction?

As part of the initial closing of the Botanico transaction, InterCure will issue 2,471,061 ordinary shares. Upon satisfaction of conditions in the share purchase agreement, it plans to issue an additional 2,470,073 ordinary shares as further consideration.

Why is InterCure (INCR) reviewing U.S. medical cannabis opportunities?

InterCure initiated a strategic review of regulated U.S. medical cannabis opportunities following recent federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III. The company is evaluating how this evolving landscape could support its international medical cannabis expansion plans.

How does the Botanico deal enhance InterCure’s product and technology portfolio?

Through the Botanico deal, InterCure gains exclusive rights to a broad collection of American cannabis genetics, proprietary strains, premium brands and advanced AI-driven, automated production systems, plus strategic brand alliances with leading U.S. operators such as The Flowery, enhancing its competitive positioning.

What progress has InterCure (INCR) made in the German medical cannabis market?

InterCure reported its first meaningful revenues from Germany’s rapidly growing medical cannabis market. To support this growth, it has appointed a German management and sales team and plans multiple product launches in the country during the second half of the year.

Is InterCure (INCR) targeting recreational cannabis in the United States?

InterCure stated that its evaluation of opportunities in the United States focuses exclusively on regulated medical cannabis markets. The company’s strategy emphasizes medical cannabis patients across multiple regulated jurisdictions rather than broader recreational cannabis activities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 09:30 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 15, 2026, InterCure Ltd. issued a press release titled “InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

Exhibit No.
99.1		Press Release issued by InterCure Ltd. on June 15, 2026, titled “InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE LTD.
Date: June 15, 2026	/s/ Amos Cohen
	Amos Cohen
	Chief Financial Officer

Exhibit 99.1

InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition

First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive  Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets.

NEW YORK and HERZLIYA, Israel, June 15, 2026 - InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. (“Botanico”), also known as ISHI, an Israeli cannabis technology and brand company  .

	●	Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III, InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets.
	●	The Botanico transaction further strengthens InterCure’s portfolio through exclusive rights to a broad collection of award-winning American cannabis genetics, proprietary strains, premium brands and advanced production technologies.
	●	Through the Botanico transaction, InterCure gains access to ISHI’s advanced AI-driven technologies, automated production systems and exclusive strategic brand alliances with leading U.S. cannabis operators, including The Flowery.
	●	As part of the initial closing of the transaction, InterCure will issue   2,471,061 ordinary shares Upon satisfaction of the conditions specified in the share purchase agreement, InterCure will issue an additional 2,470,073 ordinary shares..
	●	Earlier this year, InterCure reported its first meaningful revenues from the rapidly growing German medical cannabis market, supporting its strategy of building a leading international pharmaceutical cannabis platform.
	●	To support growing demand, InterCure has appointed a German   management and sales team and anticipates multiple product launches in the second half of the year.
	●	The Company’s evaluation of opportunities in the United States is focused exclusively on regulated medical cannabis markets.

Alexander Rabinovitch, Chief Executive Officer and Chairman of InterCure, commented, “The Botanico acquisition, German market momentum and evolving U.S. regulatory landscape support the Company’s vision of building a leading international medical cannabis company serving patients across multiple regulated markets.”

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding the expected benefits of the Botanico transaction, the Company’s integration plans, the issuance of additional consideration and other expected events pursuant to the terms of the share purchase agreement, growth opportunities in Germany, the Company’s strategic review of regulated U.S. medical cannabis opportunities, and the Company’s future strategy, product launches, operations and performance, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the ability to realize the anticipated benefits of the Botanico transaction; the successful integration of Botanico; the satisfaction of conditions under the share purchase agreement; developments in regulated U.S. medical cannabis markets; and the Company’s ability to execute its strategy in Germany and other international markets. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscape and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F, and in other filings that the Company has made and may make with the Securities and Exchange Commission in the future.

Company Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

amos@intercure.co

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 19.9 KB
• EX-99 GRAPHIC 3.7 KB